$4.51
+0.18
(+4.16%)▲
3.44%
Downside
Day's Volatility :7.93%
Upside
4.65%
49.45%
Downside
52 Weeks Volatility :73.21%
Upside
47.0%
Period | Adaptive Biotechnologies Corp | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 66.54% | 6.5% | 0.0% |
6 Months | 9.62% | 7.1% | 0.0% |
1 Year | -46.28% | 9.8% | 0.0% |
3 Years | -88.24% | 14.2% | -20.2% |
Market Capitalization | 620.4M |
Book Value | $1.87 |
Earnings Per Share (EPS) | -1.49 |
PEG Ratio | 0.0 |
Wall Street Target Price | 6.6 |
Profit Margin | -123.24% |
Operating Margin TTM | -116.45% |
Return On Assets TTM | -17.1% |
Return On Equity TTM | -61.58% |
Revenue TTM | 174.5M |
Revenue Per Share TTM | 1.2 |
Quarterly Revenue Growth YOY | 11.200000000000001% |
Gross Profit TTM | -13.7M |
EBITDA | -171.2M |
Diluted Eps TTM | -1.49 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.3 |
EPS Estimate Next Year | -1.06 |
EPS Estimate Current Quarter | -0.34 |
EPS Estimate Next Quarter | -0.33 |
What analysts predicted
Upside of 46.34%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 55.7M | ↑ 44.77% |
Net Income | -46.4M | ↑ 8.44% |
Net Profit Margin | -83.44% | ↑ 27.96% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 85.1M | ↑ 52.83% |
Net Income | -58.8M | ↑ 26.64% |
Net Profit Margin | -69.14% | ↑ 14.3% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 98.4M | ↑ 15.65% |
Net Income | -139.6M | ↑ 137.39% |
Net Profit Margin | -141.93% | ↓ 72.79% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 154.3M | ↑ 56.88% |
Net Income | -205.6M | ↑ 47.25% |
Net Profit Margin | -133.22% | ↑ 8.71% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 185.3M | ↑ 20.06% |
Net Income | -142.5M | ↓ 30.71% |
Net Profit Margin | -76.88% | ↑ 56.34% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 170.3M | ↓ 8.11% |
Net Income | -225.3M | ↑ 58.11% |
Net Profit Margin | -132.29% | ↓ 55.41% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 55.2M | ↑ 15.4% |
Net Income | -24.5M | ↓ 45.71% |
Net Profit Margin | -44.43% | ↑ 50.01% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 37.6M | ↓ 31.8% |
Net Income | -61.7M | ↑ 151.76% |
Net Profit Margin | -163.99% | ↓ 119.56% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 48.9M | ↑ 29.96% |
Net Income | -47.8M | ↓ 22.56% |
Net Profit Margin | -97.72% | ↑ 66.27% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 37.9M | ↓ 22.5% |
Net Income | -50.3M | ↑ 5.21% |
Net Profit Margin | -132.65% | ↓ 34.93% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 45.8M | ↑ 20.74% |
Net Income | -69.4M | ↑ 38.05% |
Net Profit Margin | -151.67% | ↓ 19.02% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 41.9M | ↓ 8.54% |
Net Income | -47.5M | ↓ 31.59% |
Net Profit Margin | -113.45% | ↑ 38.22% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 332.7M | ↓ 8.22% |
Total Liabilities | 590.8M | ↑ 0.63% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 912.3M | ↑ 174.22% |
Total Liabilities | 341.3M | ↓ 42.24% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 1.1B | ↑ 22.37% |
Total Liabilities | 373.1M | ↑ 9.34% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 923.3M | ↓ 17.29% |
Total Liabilities | 319.2M | ↓ 14.45% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 856.6M | ↓ 7.23% |
Total Liabilities | 392.5M | ↑ 22.95% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 661.1M | ↓ 22.82% |
Total Liabilities | 352.9M | ↓ 10.1% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 856.6M | ↓ 3.12% |
Total Liabilities | 392.5M | ↓ 0.98% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 791.5M | ↓ 7.61% |
Total Liabilities | 367.5M | ↓ 6.37% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 764.5M | ↓ 3.4% |
Total Liabilities | 368.6M | ↑ 0.29% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 717.7M | ↓ 6.13% |
Total Liabilities | 356.0M | ↓ 3.4% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 661.1M | ↓ 7.88% |
Total Liabilities | 352.9M | ↓ 0.9% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 620.3M | ↓ 6.17% |
Total Liabilities | 345.6M | ↓ 2.07% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -32.3M | ↓ 7.46% |
Investing Cash Flow | 736.0K | ↓ 97.98% |
Financing Cash Flow | 1.2M | ↓ 97.51% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 205.4M | ↓ 736.73% |
Investing Cash Flow | -481.7M | ↓ 65547.96% |
Financing Cash Flow | 319.9M | ↑ 25534.29% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -149.7M | ↓ 172.87% |
Investing Cash Flow | -117.0M | ↓ 75.7% |
Financing Cash Flow | 293.6M | ↓ 8.23% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -192.7M | ↑ 28.76% |
Investing Cash Flow | 181.2M | ↓ 254.82% |
Financing Cash Flow | 27.1M | ↓ 90.75% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -183.9M | ↓ 4.56% |
Investing Cash Flow | 2.9M | ↓ 98.4% |
Financing Cash Flow | 132.3M | ↑ 387.24% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -30.0M | ↓ 29.21% |
Investing Cash Flow | -97.5M | ↓ 268.14% |
Financing Cash Flow | 6.0K | ↓ 100.0% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -59.2M | ↑ 97.05% |
Investing Cash Flow | 63.0M | ↓ 164.56% |
Financing Cash Flow | 672.0K | ↑ 11100.0% |
Sell
Neutral
Buy
Adaptive Biotechnologies Corp is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Adaptive Biotechnologies Corp | 26.98% | 9.62% | -46.28% | -88.24% | -89.08% |
![]() Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
![]() Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
![]() Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
![]() Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Adaptive Biotechnologies Corp | NA | NA | 0.0 | -1.3 | -0.62 | -0.17 | NA | 1.87 |
![]() Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
![]() Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
![]() Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
![]() Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Adaptive Biotechnologies Corp | Buy | $620.4M | -89.08% | NA | -123.24% |
![]() Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
![]() Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Insights on Adaptive Biotechnologies Corp
Revenue is down for the last 2 quarters, 45.78M → 41.87M (in $), with an average decrease of 8.5% per quarter
Netprofit is up for the last 2 quarters, -69.44M → -47.50M (in $), with an average increase of 46.2% per quarter
In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 107.9%
In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 274.7%
Viking Global Investors LP
Vanguard Group Inc
Matrix Capital Management Company, LLC
BlackRock Inc
ARK Investment Management LLC
Rubric Capital Management LP
we are a commercial-stage, biotechnology organization located in the hot biotech locations of seattle, washington and south san francisco, ca. our world class scientists have invented a patent-pending technology that combines advances in high-throughput sequencing with state-of-the-art computer infrastructure to provide an in-depth analysis of the t- and b-cell repertoire, a specific and important part of the immune system. this information is driving the r&d community to support the fights against cancer, auto-immune disease, and much, much more. we're often asked to describe our company culture. it is very easy ... we're a hard working group of top-notch individuals who are passionate about wanting to make a difference in the world. we know our employees are our most valuable asset, and every employee’s contribution is appreciated. open communication and collaboration are always encouraged in every interaction throughout the organization. we have high expectations of ourselves, and
Organization | Adaptive Biotechnologies Corp |
Employees | 709 |
CEO | Mr. Chad M. Robins M.B.A. |
Industry | Commercial Services |
A Spac I Acquisition Corp
$4.51
+4.16%
Keyarch Acquisition Corp
$4.51
+4.16%
Connexa Sports Technologies Inc
$4.51
+4.16%
Us Value Etf
$4.51
+4.16%
First Wave Biopharma Inc
$4.51
+4.16%
Global X Msci Next Emerging
$4.51
+4.16%
Fat Projects Acquisition Corp
$4.51
+4.16%
Capital Link Global Fintech
$4.51
+4.16%
Applied Uv Inc
$4.51
+4.16%